Vimarsana
Biggest News Aggregation in the World

Fierce Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fierce Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fierce Biotech Today - Breaking & Trending Today

DiMe, Big Pharmas collab on framework for digital endpoints - Vimarsana News

DiMe, Big Pharmas collab on framework for digital endpoints

Abbvie and other big names in biopharma will work on a Digital Medicine Society project that aims to set industry benchmarks for digital endpoints.

Marinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class Action - Vimarsana News

Marinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class Action

Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. securities between March...

Stockholder Alert: Robbins LLP Informs Investors that a - Vimarsana News

Stockholder Alert: Robbins LLP Informs Investors that a

Robbins LLP is Investigating Allegations that Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding the Viability of its Drug Candidate...

MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Vimarsana News

MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

/PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has...

ASCO: Jazz shares 'unprecedented' biliary tract cancer data - Vimarsana News

ASCO: Jazz shares 'unprecedented' biliary tract cancer data

As zanidatamab awaits an FDA decision, Jazz is sharing long-term phase 2 data in advanced biliary tract cancer for the HER2-targeted bispecific antibody.